Table 2

Results of genotype risk score analysis of the 11 “lipodystrophy-like” variants

Category/traitUnitPer-allele β95% CIPN
Nondisease metabolic traits of monogenic IR
 SHBG (BMI adjusted)Natural log−0.010−0.012, −0.0089 × 10−1321,000
 HDL-CSD−0.020−0.024, −0.0167 × 10−3799,900
 Adiponectin (BMI adjusted)log−0.015−0.017, −0.0132 × 10−2629,346
 BMISD−0.008−0.012, −0.0047 × 10−8123,865
 VATSAT ratioz-score0.0150.009, 0.0216 × 10−710,557
 CT-measured hepatic steatosisSD0.0210.009, 0.0333 × 10−47,176
 ALTlog100.0020.001, 0.0033 × 10−555,474
 TriglycerideSD0.0180.014, 0.0224 × 10−2996,598
Metabolic disease and disease-related outcomes
 T2DOR1.0431.031, 1.0555 × 10−1312,171 vs. 56,862
 CADOR1.0131.007, 1.0191 × 10−540,365 vs. 63,714
 Systolic blood pressure (BMI adjusted)mmHg0.1350.072, 0.1982 × 10−569,828
 Diastolic blood pressure (BMI adjusted)mmHg0.0750.036, 0.1142 × 10−469,816
 cIMTlog0.000−0.002, 0.0020.7031,210
 Carotid plaquesOR1.0050.991, 1.0190.5025,179
  • The 8 nondisease metabolic traits were used to select the 11 variants, so associations are not independent of the clustering process. The metabolic disease outcomes were not used in the clustering process and so represent independent tests. VATSAT, visceral-to-subcutaneous adipose tissue. P values ≤ 0.001 are in bold.